Beta Drugs growth ratios
Per cent unless marked ×
| Tap a line for its trend | FY26Mar 2026 |
|---|
| +6.2% | |
| +1.4% | |
| −5.7% | |
| −2.2% | |
| −2.6% | |
| +13.7% | |
| +18.0% |
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
| Tap a line for its trend | FY26Mar 2026 |
|---|
| +6.2% | |
| +1.4% | |
| −5.7% | |
| −2.2% | |
| −2.6% | |
| +13.7% | |
| +18.0% |
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
Ratios — % unless marked × 12 Months Ending | FY25 31/03/2025 | FY26 31/03/2026 | Last 12M 30/09/2026 | |
|---|---|---|---|---|
| Revenue Growth | — | +6.2 | — | |
| EBITDA Growth | — | +1.4 | — | |
| EBIT Growth | — | -5.7 | — | |
| Net Income Growth | — | -2.2 | — | |
| EPS Growth | — | -2.6 | — | |
| Total Assets Growth | — | +13.7 | — | |
| Cash from Operations Growth | — | +18.0 | — |